Danielle Stutzman, PharmD, BCPP

As centanafadine awaits DEA scheduling, Megan Maroney, PharmD, BCPP, FAAPP, and Danielle Stutzman, PharmD, BCPP, unpack what its modest efficacy data, favorable interaction profile, and pediatric dosing considerations mean for real-world ADHD prescribing.

Maroney and her guest, Danielle Stutzman, PharmD, BCPP, break down efficacy data and potential advantages of centanafadine, the newly approved triple reuptake inhibitor for ADHD.